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ABSTRACT 
 
Background: Dietary intake of long-chain n-3 PUFA (LCn3FA) among Japanese is generally higher 
than that in Western populations. However, little is known whether an inverse association of LCn3FA 
with cardiovascular disease (CVD) risk exists in a population with higher LCn3FA intake. 
 
Objective: To investigate the association between LCn3FA intake and the long-term risk of CVDs in a 
Japanese general population. 
 
Methods: We followed-up a total of 9,190 individuals (56.2% women, mean age 50.0 years) randomly 
selected from 300 areas across Japan and free from CVDs at baseline. Dietary LCn3FA intake was 
estimated using household weighed food records. Cox models were used to calculate 
multivariate-adjusted hazard ratios (HR) and confidence intervals (CI) according to sex specific 
quartiles of LCn3FA intake.  
 
Results: During 24-year follow-up (192,897 person-years), 879 cardiovascular deaths were observed. 
The median daily intake of LCn3FA was 0.37%kcal (0.86 g/day). Adjusted HR for CVD mortality was 
lower in the highest quartile of LCn3FA intake (HR 0.80; 95%CI 0.66-0.96) compared with the lowest 
quartile, and the trend was statistically significant (P=0.038). The similar but statistically 
non-significant trends were observed for coronary heart disease death and stroke death. In analyses by 
age groups, the inverse associations of LCn3FA intake with the risk of total CVD death and stroke 
death were significant in younger individuals (30-59 years at baseline). 
 
Conclusion: LCn3FA intake was inversely and independently associated the long-term risk of total 
CVD mortality in a representative sample of Japanese with high LCn3FA intake. 
 
Keywords: long-chain n-3 polyunsaturated fatty acid; cardiovascular disease mortality; nutrition; 
cohort study  
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1. Introduction 
Long-chain n-3 PUFA (LCn3FA) intake was shown to be inversely associated with the risk 
of cardiovascular diseases (CVD), particularly that of coronary heart disease (CHD), mainly in 
Western populations.[1] A protective effect of fish and LCn3FA consumption on stroke risk was also 
suggested from some recent meta-analyses.[2, 3] The previous studies suggested that the effect of 
LCn3FA on CHD death has a dose-response relationship with a ceiling effect at their dose of around 
600 mg/day.[4] 
Major origins of dietary LCn3FA are fish and shellfish. Many studies in Western countries 
showed the association of fish and LCn3FA consumption with CVD risk compared with non fish 
eaters. Average fish intake, therefore LCn3FA intake, of Japanese is markedly higher compared with 
that of Western populations - approximately 3 to 4 times higher for fish intake and 6 to 10 times higher 
for LCn3FA intake.[5-7] There have been only three prospective cohort studies on fish/LCn3FA intake 
and CVD risk from Japan,[8-10] but their dietary data were from food frequency questionnaire (FFQ); 
therefore, results were not controlled for sodium intake, which generally correlates with fish intake in 
Japan.[11] Therefore, little evidence exists whether LCn3FA intake in a higher range relates to 
long-term CVD risk independent from sodium intake using high-quality dietary data. 
In this report, we examined the association of dietary LCn3FA intake, estimated by 3-day 
weighed food records in the National Nutritional Survey of Japan (NNSJ), with 24-year CVD 
mortality risk in a representative Japanese population where dietary intake of LCn3FA is substantially 
higher than typical Western diet.  
 
2. Subjects and methods 
2.1 Participants 
The National Integrated Project for Prospective Observation of Non-communicable Disease 
And its Trends in the Aged (NIPPON DATA) is a series of cohort studies, which utilize as a baseline 
survey both the National Survey on Circulatory Disorders and the NNSJ conducted in 1980 and 1990 
by the Ministry of Health and Welfare, Japan. We analyzed the data of NIPPON DATA80 in which the 
baseline survey was conducted in 1980. The details of these cohorts previously were reported 
elsewhere.[12, 13] 
In brief, a total of 10,546 community residents (4,639 men and 5,907 women, aged 30 and 
greater) from 300 randomly selected districts from all-over Japan participated in the survey, with the 
participation rate of about 77%. Accordingly, these participants were thought to be representative of 
the Japanese population. A total of 1,356 men and women excluded from this analysis for the 
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following reasons: history of CVD (n=350), missing information (e.g., nutrition, lifestyle 
questionnaire) at baseline (n=124), intake of energy more than 5,000 kcal/day or less than 500 
kcal/day (n=139) and lost to follow-up due to incomplete residential addresses at the baseline survey 
(n=1104). We included the remaining 9,190 participants (4,028 men and 5,162 women) in the analysis. 
 
2.2 Follow-up and Outcomes 
The participants were followed until November 2004, providing 24 years of follow up. Vital 
status of participants was followed up using registration records in local governments where they lived. 
National Vital Statistics were utilized to identify the causes of death with permission from the 
Management and Coordination Agency, Government of Japan. The underlying causes of death in the 
National Vital Statistics were coded according to the 9th International Classification of Disease (ICD 9) 
until the end of 1994, and the 10th International Classification of Disease (ICD 10) from the beginning 
of 1995. The details of classification were described elsewhere.[13] The corresponding ICD9 and 
ICD10 codes were as follows: cardiovascular mortality, 393 to 459 (ICD9), I00 to I99 (ICD10); 
coronary heart disease mortality, 410 to 414 (ICD9), I20 to I25 (ICD10); and stroke mortality, 430 to 
438 (ICD9), I60 to I69 (ICD10). We obtained approval for the study from the Institutional review 
Board of Shiga University of Medical Science (No.12-18, 2000; No.17-21-1, 2010). 
 
2.3 Baseline examination 
At baseline, non-fasting blood samples were obtained. Serum was separated and centrifuged 
soon after blood coagulation. Plasma samples were also obtained in a siliconized tube containing 
sodium fluoride. These samples were shipped to one laboratory (SRL, Tokyo) for blood measurements. 
Plasma glucose and serum total cholesterol were measured enzymatically. Lipid measurements were 
standardized by the Centers for Disease Control / National Heart, Lung, and Blood Institute 
(CDC-NHLBI) Lipids Standardization Program.[14] 
 Body mass index (BMI) was calculated as weight (kg) divided by the square of height (m). 
Trained observers measured baseline blood pressures by using a standard mercury 
sphygmomanometer on the right arm of seated participants. Public health nurses obtained information 
on smoking, drinking, and medical histories. We divided participants into three categories of smoking 
(never-smoked; ex-smoker; current smoker) and three categories of drinking (never-drinker; 
ex-drinker; current drinker). 
 
2.4 Dietary Assessment 
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We used the data of NNSJ in 1980 (NNSJ80). Detailed methods of the dietary assessment, the 
estimation of individual intake of nutrients, and food groups were described elsewhere.[15-17] In brief, 
food intake survey by weighed food records in three consecutive representative days in each 
household were conducted by specially trained dietary interviewers. Dietary interviewers visited 
participants’ house at least once during the survey, avoiding weekends and holidays. Modified 
Standards Tables for Food Composition in Japan, 3rd edition, with matched fatty acid values and 
micronutrients, were used to estimate nutrient intakes in each household for NNSJ80. Nutrient intakes 
of each household member were estimated by dividing household intake data of NNSJ80 
proportionally using average intake by sex and age groups calculated for NNSJ conducted in 1995 
(NNSJ95). The average intake in NNSJ95 were assessed by a combination method of household-based 
weighed food records and an approximation of proportions by which family members shared each dish 
or food in the household. For each person, means of the estimated individual nutrients from the three 
day records were used in the analyses. Dietary researchers were blinded to participant outcome status.  
 For energy supplying nutrients, the intake was calculated as the percent of total energy intake 
(%kcal). Other nutrients were calculated relative to total dietary intake (g/1,000 kcal). LCn3FA was 
the sum of eicosapentaenoic acid (EPA) and docosapentaenoic acid (DHA). 
 
2.5 Statistical Analysis 
Baseline characteristics and nutritional parameters of participants were presented as means 
and standard deviations for continuous variables and as numbers and percentages for categorical 
variables. Differences in baseline characteristics and nutritional parameters among sex specific 
quartiles of LCn3FA intake were evaluated using trend analysis or chi-square test.  
Cox proportional-hazards regression models were used to estimate the multivariate-adjusted 
hazard ratios (HR) of death from total CVD and components of CVDs according to quartiles of 
LCn3FA intake. Model 1 represents the model adjusted for age and sex. Model 2 was additionally 
adjusted for the conventional risk factors: BMI, smoking status (never, ex, and current), drinking 
status (never, ex, and current), antihypertensive medication status (yes or no), systolic blood pressure 
(mm Hg), serum total cholesterol (mg/dl), blood glucose (mg/dl) and residential area (population size 
≤10,000, 10,001-50,000, 50,001-300,000, and ≥300,001). Model 3 was further adjusted for nutritional 
parameters in addition to the variables adjusted in Model 2: saturated fatty acids, total n-6 
polyunsaturated fatty acid (PUFA), vegetable protein, fiber and sodium. Stratified analyses were 
conducted by age groups (30-59 years, ≥60 years at baseline) or by sexes. Corresponding analyses 
were done also for total n-3 PUFA intake and for EPA and DHA intake, separately, intake instead of 
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LCn3FA intake. Tests for trend involved assigning participants the median value in their quartiles of 
fatty acids intake and evaluating this as a continuous variable. 
The statistical analyses were performed by SPSS for Windows Version 18.0 (SPSS Japan Inc., 
Tokyo, Japan). All probability values were two-sided, and P values less than 0.05 were considered 
statistically significant. 
 
3. Results 
Table 1 shows the baseline characteristics of study participants according to quartiles of 
LCn3FA intake. The median daily intake of LCn3FA in total participants was 0.37%kcal (0.86 g/day). 
As the amount of LCn3FA intake increased, age, systolic blood pressure, blood glucose and dietary 
intake of sodium increased; in contrast, dietary energy intake, total fat intake, total n-6 PUFA intake 
and proportion of population resident in a metropolitan area decreased. Observed total person-years 
were 192,897, and the mean follow-up period was 21.0 years. During the follow-up, 879 participants 
died from total CVD (including 171 from CHD, 417 from stroke, 170 from heart failure) and 1,672 
died from non-CVD. 
Table 2 shows multivariate-adjusted HRs and 95% CIs according to sex-specific quartiles of 
LCn3FA intake. HRs of total CVD death were significantly lower in the highest quartile of LCn3FA 
intake (Q4) (HR 0.80 [95% CI 0.66-0.96]) compared with the lowest quartile (Q1) in model 3, and its 
inverse linear trend was statistically significant in model 3 (P =0.038). The tendency of HRs in 
relation to LCn3FA intake was similar for CHD death, but not statistically significant. HR of stroke in 
the highest quartile (Q4) was 0.75 (95%CI 0.57-1.00), although the trend was not statistically 
significant (P =0.115). There were no statistically significant associations between LCn3FA intake and 
non-CVD mortality risk.  
Table 3 shows results by age groups at baseline. The associations of LCn3FA intake with 
total CVD death and stroke death were significant for younger group (30-59 years at baseline). Inverse 
associations were observed both in men and women (Online Supplement Table 1). 
When the analyses were done according to the quartiles of total n-3 PUFA intake, the results 
were similar; however, the associations were weaker than those for LCn3FA (Online Supplement 
Table 2). The association of alpha linoleic acid, the main part of non-LCn3FA, with CVD death was 
not significant (data not shown). HRs according to the quartiles of EPA or DHA intake showed similar 
inverse associations; although the trend was somewhat stronger for DHA intake (Online Supplement 
Tables 3 and 4). 
Based on an examination of more complex models that include tests of interaction and 
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non-linearity, we did not detect any significant departures from the assumption of proportionality.  
 
4. Discussion 
In this 24-year, community-based, prospective cohort study of representative Japanese, we 
observed an inverse association between LCn3FA intake and risk of CVD mortality after adjustment 
for cardiovascular risk factors and nutritional factors including sodium intake. The association was 
significant for younger individuals aged 30-59 years at baseline. The association was not significant 
for older individuals aged 60 years or over. 
The relative strength of effect is estimated from effects of LCn3FA on each risk factor and on 
the corresponding impact on cardiovascular risk. For example, dose- response for antiarrhythmic, 
blood pressure lowering and heart rate lowering effects are initially steep with a subsequent plateau at 
0.5 g/day, 0.75 g/day and 0.75 g/day, respectively.[4] In our study, 30% of participants ingested 
LCn3FA 1 g/day or over and 90% of participants ingested 0.5 g/day or over; almost all participants in 
the present study have ingested high amount of LCn3FA. We observed dose-dependently lower risk of 
CVD mortality, and multivariate-adjusted HRs (95% CI) for the highest (median intake of LCn3FA 
was 0.68% energy; 1.6 g/day) versus lowest (median intake of LCn3FA was 0.18% energy; 0.4 g/day) 
quartiles of LCn3FA intake was 0.80 (0.66 to 0.96). Median value of the lowest quartile of LCn3FA 
intake in the present study was twice as high as the average intake in U.S. population.[18] Namely, our 
long-term cohort study indicated that a higher intake of LCn3FA was associated with reduced 
long-term risk of CVD compared with a modest LCn3FA intake. Recent studies show that LCn3FA 
exert many actions on cell physiology and functions, including assembly of signaling platform, i.e., 
lipid rafts, and intracellular signaling cascades leading to gene expression.[19] These actions most 
likely require intakes of LCn3FA above 1 g/day, which many Japanese in Japan regularly consumed. 
Thus, these effects might be associated with our observation.  Moreover, our results suggested that 
other n-3 PUFAs, mainly alpha linoleic acid from vegetable sources, do not have a protective effect 
for CVD. 
Only three prospective cohort studies reported the association of dietary fish intake or 
LCn3FA with CVD in Japanese. Two of the studies evaluated food and nutrient intake using FFQ, and 
their follow-up period was shorter (about 10 years) than ours. Although the previous three studies in 
Japan showed no significant associations for stroke risk, we observed a significant inverse relationship 
of LCn3FA to the risk of stroke mortality in younger age group. In addition, no previous studies in 
Japan showed HRs adjusted for sodium intake. Higher fish intake would coexist with higher sodium 
intake due to traditional Japanese dietary pattern; therefore, the inverse association of LCn3FA with 
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CVD risk could be under-estimated without adjustment of sodium intake. Our study would be the first 
to show the relationship between n-3 PUFA intake and stroke risk with adjustment of sodium intake. 
There have been several randomized controlled trials supplementing 0.4-0.9 g/day EPA and 
DHA in Western populations.[1] The Japan EPA Lipid Intervention Study [20] demonstrated a 
protective effect of EPA supplementation (1.8 g/day) on nonfatal coronary events for 4.6 years, but 
effect on fatal coronary events was not confirmed. In addition, almost all trials were for secondary 
prevention or for primary prevention in high risk individuals, and their follow-up period was shorter (1 
to 6 years).[20, 21] Long-term effect of n-3 PUFA on primary prevention of CVD in general 
population may only be investigated by long-term observational studies. In our study, a significant 
association between LCn3FA intake and reduce mortality from total CVD and stroke was observed in 
individuals that were 30-59 years at baseline but not in individuals who were 60 years or older at 
baseline. The lack of association who were older individuals at baseline may due to a variety of factors 
such as survivor effect, poorer nutrition in their younger age, or dietary modification or medical 
treatment in high risk individuals. 
There have been few previous large-scale cohort studies using weighed food records for 
dietary assessment to investigate LCn3FA intake and CVD risk. It was reported that correlations of 
plasma phospholipid fatty acids with intake of total n-3 PUFA, EPA and DHA by weighed food 
records were stronger than those by FFQ.[22] Furthermore, studies in Japanese showed that 
correlations between serum fatty acids and intake of EPA, DHA and total n-3 PUFA evaluated by 
seven-days weighed food records were high (correlation coefficients 0.47-0.86).[23, 24]  
There are several limitations in this study. First, the follow-up period of our study was long, 
and dietary exposure may have changed over time.[25] Also, we assumed that smoking habit and other 
confounding factors, adjusted in multivariate-adjusted models, did not change during the follow-up 
period. Second, information on fish oil supplementation was not available in the baseline survey, 
although supplement use was not common among Japanese in 1980. Third, we cannot exclude residual 
confounding from unmeasured or unknown factors. For example, physical activity, socioeconomic 
status and amount of alcohol consumption were not considered in this analysis. Fourth, we did not 
have data on CVD incidence; therefore, we could not examine the relationships to CVD incidence. 
Fifth, we used non-fasting blood glucose for adjustment, although we reported a positive relationship 
of non-fasting blood glucose to CVD risk from this cohort study.[26] Finally, there may be potential 
misclassifications in causes of deaths from vital statistics, although data on total CVD mortality would 
be more reliable. 
In conclusion, this long-term cohort study of representative Japanese showed that a higher 
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amount of long-chain n-3 PUFA intake would lower the long-term risk of cardiovascular disease 
mortality, especially in younger adults.
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Table 1. Baseline characteristics of cardiovascular risk factors and selected dietary variables in 4,028 men and 5,162 women by the quartiles of LCn3FA 
intake: NIPPON DATA80, 1980 
Quartiles of LCn3FA intake, %kcal P value a 
Q1 (Low) Q2 Q3 Q4 (High) 
Range of LCn3FA intake (median), %kcal  
Men 0.00-0.23 (0.18) 0.24-0.35 (0.29) 0.36-0.51 (0.43) 0.52-2.34 (0.65) 
Women 0.02-0.25 (0.19) 0.26-0.38 (0.32) 0.39-0.55 (0.46) 0.56-2.43 (0.70) 
Mean intake of LCn3FA, g/day 0.42 (0.15) 0.74 (0.17) 1.06 (0.25) 1.72 (0.62) < 0.001 
Number at risk 2263 2374 2257 2296 
Number of women, % 56.1 56.6 56.0 56.0 0.975 
Age at baseline, years 49.4 (13.3) 49.4 (13.0) 50.5 (13.1) 50.8 (13.3) < 0.001 
Body mass index, kg/m2 22.6 (3.2) 22.7 (3.1) 22.6 (3.1) 22.9 (3.2) 0.005 
Systolic blood pressure, mm Hg 134.9 (20.7) 135.5 (21.5) 136.1 (21.4) 136.7 (21.2) 0.002 
Diastolic blood pressure, mm Hg 81.2 (12.3) 81.1 (12.1) 81.4 (12.3) 81.5 (12.2) 0.229 
Antihypertensive medication, % 9.9 12.1 12.0 13.3 0.024 
Casual blood glucose, mg/dL 98.3 (27.5) 100.4 (31.3) 100.6 (28.5) 101.0 (32.1) 0.003 
Serum total cholesterol, mg/dL 188.0 (33.5) 188.7 (33.8) 190.5 (34.1) 187.9 (33.2) 0.602 
Current smoker, % 33.7 31.8 32.0 33.7 0.141 
Current drinker, % 43.0 44.6 43.3 44.9 0.789 
Resident in metropolitan area, % 30.4 28.4 27.9 22.6 < 0.001 
Intake of nutrients and foods 
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Total energy, kcal/day 2155 (500) 2167 (468) 2132 (478) 2100 (510) < 0.001 
Total fat, %kcal 21.2 (5.7) 21.0 (5.4) 20.4 (5.3) 20.3 (5.4) < 0.001 
Saturated fatty acids, %kcal 6.0 (1.7) 5.9 (1.5) 5.8 (1.5) 5.9 (1.5) 0.026 
Total n-6 PUFA, %kcal 4.4 (1.2) 4.3 (1.2) 4.3 (1.2) 4.2 (1.2) < 0.001 
Total n-3 PUFA , %kcal 0.9 (0.3) 1.0 (0.3) 1.2 (0.3) 1.5 (0.4) < 0.001 
Eicosapentaenoic acid, %kcal 0.06 (0.02) 0.11 (0.02) 0.17 (0.02) 0.29 (0.09) < 0.001 
Docosahexaenoic acid, %kcal 0.11 (0.03) 0.19 (0.02) 0.28 (0.03) 0.46 (0.13) < 0.001 
Vegetable protein, %kcal 7.4 (1.0) 7.4 (0.9) 7.4 (0.9) 7.5 (1.1) 0.059 
Total dietary fiber, g/1,000kcal 8.4 (2.0) 8.5 (2.0) 8.6 (2.1) 8.6 (2.2) 0.007 
Sodium, mg/1,000kcal 2350 (746) 2522 (790) 2631 (776) 2906 (1000) < 0.001 
Fish and shellfish, g/1,000kcal 30.9 (14.2) 44.5 (16.0) 55.0 (18.1) 75.0 (26.0) < 0.001 
Values are means (standard deviation) or %. a Differences were evaluated using trend analysis or chi-square test. 
LCn3FA, long-chain n-3 polyunsaturated fatty acids; PUFA, polyunsaturated fatty acid.
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Table 2. Multivariate-adjusted HRs and 95% CIs of mortality from total cardiovascular diseases, coronary heart disease, stroke, and total non-cardiovascular 
diseases according to quartiles of LCn3FA intake: NIPPON DATA80 
  Quartiles of LCn3FA intake P value for trend 
  Q1 (Low) Q2 Q3 Q4 (High) 
Person-years 47402  50196  47359  47940  
Total cardiovascular disease deaths, n 222 210 216 231 
Model 1 1 0.90 (0.75-1.09) 0.90 (0.74-1.08) 0.90 (0.75-1.09) 0.358  
Model 2 1 0.87 (0.72-1.05) 0.88 (0.73-1.06) 0.85 (0.70-1.02) 0.144  
Model 3 1 0.85 (0.70-1.03) 0.85 (0.70-1.03) 0.80 (0.66-0.96) 0.038  
Coronary heart disease deaths, n 39 43 43 46 
Model 1 1 1.04 (0.68-1.61) 1.00 (0.65-1.55) 1.02 (0.66-1.56) 0.994  
Model 2 1 1.01 (0.66-1.57) 0.95 (0.61-1.46) 0.94 (0.61-1.45) 0.713  
Model 3 1 0.95 (0.61-1.47) 0.88 (0.57-1.36) 0.82 (0.53-1.29) 0.363  
Stroke death, n 104 95 112 106 
Model 1 1 0.87 (0.66-1.15) 0.99 (0.76-1.30) 0.89 (0.68-1.17) 0.583  
Model 2 1 0.82 (0.62-1.08) 0.97 (0.74-1.27) 0.81 (0.62-1.06) 0.267  
Model 3 1 0.81 (0.61-1.07) 0.94 (0.72-1.24) 0.75 (0.57-1.00) 0.115  
Total non-cardiovascular disease deaths, n 392 421 416 443 
Model 1 1 1.00 (0.87-1.15) 0.96 (0.84-1.10) 0.98 (0.86-1.13) 0.714  
Model 2 1 1.00 (0.87-1.14) 0.97 (0.84-1.11) 0.97 (0.85-1.12) 0.637  
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Model 3 1 1.00 (0.87-1.15) 0.97 (0.85-1.12) 0.97 (0.84-1.12) 0.562  
Model 1 was adjusted for age and sex. Model 2 was adjusted for variables in Model 1 plus smoking status, drinking status, systolic blood pressure, blood 
glucose, serum total cholesterol, body mass index, antihypertensive medication status and residential area. Model 3 was adjusted for variables in Model 2 plus 
dietary intakes of saturated fatty acids (%kcal), total n-6 PUFA (%kcal), vegetable protein (%kcal), total dietary fiber (g/1,000kcal) and sodium 
(mg/1,000kcal). 
LCn3FA, long-chain n-3 polyunsaturated fatty acids; HR, hazard ratio; CI, confidence interval; PUFA, polyunsaturated fatty acid.
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Table 3. Multivariate-adjusted HRs and 95% CIs of mortality from total cardiovascular diseases, coronary heart disease and stroke according to quartiles of 
LCn3FA intake by age groups: NIPPON DATA80 
  Quartiles of LCn3FA intake P value for trend 
  Q1 (Low) Q2 Q3 Q4 (High) 
Total cardiovascular disease deaths 
30-59 years at baseline 
Number of deaths 57 62 56 59 
Model 1 1 0.95 (0.66-1.36) 0.82 (0.57-1.19) 0.83 (0.58-1.20) 0.271 
Model 2 1 0.94 (0.65-1.35) 0.77 (0.53-1.12) 0.75 (0.51-1.08) 0.085 
Model 3 1 0.92 (0.64-1.32) 0.75 (0.51-1.09) 0.68 (0.46-1.00) 0.031 
≥60 years at baseline  
Number of deaths 165 148 160 172 
Model 1 1 0.89 (0.71-1.11) 0.93 (0.75-1.15) 0.93 (0.75-1.15) 0.665 
Model 2 1 0.87 (0.70-1.09) 0.93 (0.75-1.16) 0.91 (0.73-1.13) 0.564 
Model 3 1 0.86 (0.68-1.07) 0.91 (0.73-1.13) 0.86 (0.69-1.08) 0.323 
Coronary heart disease deaths 
30-59 years at baseline  
Number of deaths 13 15 13 13 
Model 1 1 1.00 (0.47-2.10) 0.83 (0.38-1.79) 0.79 (0.36-1.71) 0.472  
Model 2 1 0.98 (0.46-2.08) 0.79 (0.36-1.72) 0.77 (0.35-1.69) 0.440  
Model 3 1 0.94 (0.44-1.99) 0.75 (0.34-1.66) 0.70 (0.31-1.60) 0.341  
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≥60 years at baseline  
Number of deaths 26 28 30 33 
Model 1 1 1.05 (0.61-1.79) 1.07 (0.63-1.82) 1.11 (0.66-1.86) 0.685  
Model 2 1 1.07 (0.63-1.84) 1.06 (0.62-1.80) 1.10 (0.65-1.85) 0.758  
Model 3 1 0.99 (0.57-1.70) 0.97 (0.57-1.66) 0.95 (0.55-1.63) 0.827  
Stroke deaths 
30-59 years at baseline  
Number of deaths 24 32 31 25 
Model 1 1 1.17 (0.69-1.98) 1.10 (0.64-1.87) 0.85 (0.48-1.49) 0.416 
Model 2 1 1.15 (0.68-1.96) 1.02 (0.60-1.75) 0.71 (0.40-1.25) 0.133 
Model 3 1 1.10 (0.64-1.87) 0.95 (0.55-1.64) 0.59 (0.33-1.08) 0.043 
≥60 years at baseline  
Number of deaths 80 63 81 81 
Model 1 1 0.78 (0.56-1.09) 0.97 (0.71-1.32) 0.91 (0.66-1.23) 0.878 
Model 2 1 0.73 (0.52-1.02) 0.95 (0.70-1.30) 0.85 (0.62-1.16) 0.665 
Model 3 1 0.73 (0.52-1.03) 0.95 (0.69-1.30) 0.81 (0.59-1.13) 0.497 
Model 1 was adjusted for age and sex. Model 2 was adjusted for variables in Model 1 plus smoking status, drinking status, systolic blood pressure, blood 
glucose, serum total cholesterol, body mass index, antihypertensive medication status and residential area. Model 3 was adjusted for variables in Model 2 plus 
dietary intakes of saturated fatty acids (%kcal), total n-6 PUFA (%kcal), vegetable protein (%kcal), total dietary fiber (g/1,000kcal) and sodium 
(mg/1,000kcal).    
LCn3FA, long-chain n-3 polyunsaturated fatty acids; HR, hazard ratio; CI, confidence interval; PUFA, polyunsaturated fatty acid. 
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Online Supplement Table 1. Multivariate-adjusted HRs and 95% CIs of mortality from total cardiovascular diseases, coronary heart disease and 
stroke according to quartiles of LCn3FA intake by sexes: NIPPON DATA80 
  Quartiles of LCn3FA intake P value for trend 
  Q1 (Low) Q2 Q3 Q4 (High) 
Total cardiovascular disease deaths 
  Men 
    Model 1 1 0.82 (0.63-1.08) 0.87 (0.67-1.14) 0.89 (0.68-1.15) 0.599 
    Model 2 1 0.80 (0.61-1.05) 0.87 (0.67-1.13) 0.87 (0.66-1.13) 0.537 
    Model 3 1 0.79 (0.60-1.04) 0.84 (0.64-1.10) 0.79 (0.60-1.04) 0.204 
  Women 
    Model 1 1 0.99 (0.76-1.29) 0.91 (0.70-1.19) 0.89 (0.69-1.16) 0.322 
    Model 2 1 0.95 (0.73-1.25) 0.88 (0.67-1.15) 0.82 (0.63-1.07) 0.113 
    Model 3 1 0.94 (0.72-1.23) 0.86 (0.66-1.13) 0.78 (0.60-1.03) 0.066 
Coronary heart disease deaths 
  Men 
    Model 1 1 1.02 (0.55-1.86) 0.84 (0.45-1.57) 1.01 (0.55-1.84) 0.949  
    Model 2 1 1.00 (0.54-1.83) 0.78 (0.41-1.47) 0.98 (0.53-1.80) 0.862  
    Model 3 1 0.93 (0.50-1.73) 0.73 (0.39-1.38) 0.86 (0.46-1.62) 0.582  
  Women 
    Model 1 1 1.10 (0.59-2.04) 1.18 (0.65-2.16) 1.02 (0.55-1.87) 0.999  
    Model 2 1 1.02 (0.55-1.92) 1.11 (0.61-2.04) 0.92 (0.50-1.71) 0.783  
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    Model 3 1 0.98 (0.52-1.85) 1.04 (0.57-1.91) 0.81 (0.43-1.54) 0.505  
Stroke deaths 
  Men 
    Model 1 1 0.80 (0.54-1.18) 0.94 (0.65-1.36) 0.90 (0.62-1.30) 0.839 
    Model 2 1 0.76 (0.51-1.12) 0.94 (0.65-1.36) 0.84 (0.57-1.23) 0.667 
    Model 3 1 0.76 (0.51-1.13) 0.92 (0.63-1.34) 0.78 (0.53-1.16) 0.408 
  Women 
    Model 1 1 0.94 (0.63-1.40) 1.04 (0.70-1.53) 0.85 (0.57-1.26) 0.467 
    Model 2 1 0.90 (0.60-1.34) 1.01 (0.68-1.49) 0.76 (0.51-1.13) 0.203 
    Model 3 1 0.89 (0.59-1.33) 0.99 (0.67-1.47) 0.71 (0.47-1.07) 0.124 
Model 1 was adjusted for age. Model 2 was adjusted for variables in Model 1 plus smoking status, drinking status, systolic blood pressure, blood glucose, 
serum total cholesterol, body mass index, antihypertensive medication status and residential area. Model 3 was adjusted for variables in Model 2 plus dietary 
intakes of saturated fatty acids (%kcal), total n-6 PUFA (%kcal), vegetable protein (%kcal), total dietary fiber (g/1,000kcal) and sodium (mg/1,000kcal). 
   
LCn3FA, long-chain n-3 polyunsaturated fatty acids; HR, hazard ratio; CI, confidence interval; PUFA, polyunsaturated fatty acid. 
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Online Supplement Table 2. Multivariate-adjusted HRs and 95% CIs of mortality from total cardiovascular diseases, coronary heart disease and 
stroke according to quartiles of total n-3 fatty acid intake: NIPPON DATA80 
  Quartiles of total n-3 fatty acid intake P value for trend 
  Q1 (Low) Q2 Q3 Q4 (High) 
Range of total n-3 fatty acid intake, %kcal 
Men 0.20-0.85 0.86-1.05 1.06-1.28 1.29-3.92 
Women 0.21-0.93 0.94-1.15 1.16-1.39 1.40-3.66 
Person-years 45771  49814  48873  48438  
Total cardiovascular disease deaths, n 281 222 179 197 
  Model 1 1 0.95 (0.79-1.13) 0.87 (0.72-1.05) 0.92 (0.77-1.11) 0.265  
  Model 2 1 0.95 (0.80-1.14) 0.85 (0.71-1.03) 0.91 (0.76-1.09) 0.187  
  Model 3 1 0.94 (0.78-1.13) 0.83 (0.68-1.01) 0.85 (0.68-1.06) 0.092  
Coronary heart disease deaths, n 52 47 34 38 
  Model 1 1 1.05 (0.71-1.56) 0.85 (0.55-1.32) 0.92 (0.60-1.40) 0.518  
  Model 2 1 1.06 (0.71-1.57) 0.81 (0.52-1.25) 0.89 (0.58-1.36) 0.395  
  Model 3 1 1.12 (0.75-1.70) 0.89 (0.56-1.41) 0.99 (0.60-1.65) 0.759  
 
      
Stroke deaths, n 127 107 92 91 
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  Model 1 1 1.01 (0.78-1.31) 0.99 (0.76-1.29) 0.95 (0.72-1.24) 0.638  
  Model 2 1 1.02 (0.79-1.32) 0.99 (0.75-1.29) 0.91 (0.69-1.20) 0.449  
  Model 3 1 0.96 (0.73-1.25) 0.89 (0.67-1.19) 0.74 (0.53-1.04) 0.064  
Model 1 was adjusted for age and sex. Model 2 was adjusted for variables in Model 1 plus smoking status, drinking status, systolic blood pressure, blood 
glucose, serum total cholesterol, body mass index, antihypertensive medication status and residential area. Model 3 was adjusted for variables in Model 2 plus 
dietary intakes of saturated fatty acids (%kcal), total n-6 PUFA (%kcal), vegetable protein (%kcal), total dietary fiber (g/1,000kcal) and sodium 
(mg/1,000kcal). 
HR, hazard ratio; CI, confidence interval; PUFA, polyunsaturated fatty acid.
21 
 
 
Online Supplement Table 3. Multivariate-adjusted HRs and 95% CIs of mortality from total cardiovascular diseases, coronary heart disease and 
stroke according to quartiles of eicosapentaenoic acid: NIPPON DATA80 
  Quartiles of EPA intake P value for trend 
  Q1 (Low) Q2 Q3 Q4 (High) 
Range of EPA intake, %kcal 
Men 0.00-0.08 0.09-0.13 0.14-0.19 0.20-0.95 
Women 0.00-0.09 0.10-0.14 0.15-0.21 0.22-0.98 
Person-years 49312  49840  45546  48200  
Total cardiovascular disease deaths, n 221 220 201 237 
Model 1 1 0.93 (0.77-1.12) 0.90 (0.74-1.09) 0.93 (0.77-1.11) 0.454  
Model 2 1 0.92 (0.76-1.11) 0.88 (0.72-1.06) 0.89 (0.74-1.07) 0.209  
Model 3 1 0.90 (0.75-1.09) 0.85 (0.70-1.03) 0.83 (0.69-1.00) 0.057  
Coronary heart disease deaths, n 41 44 41 45 
Model 1 1 1.00 (0.65-1.53) 0.98 (0.63-1.50) 0.95 (0.62-1.45) 0.773  
Model 2 1 1.01 (0.66-1.54) 0.92 (0.59-1.42) 0.89 (0.58-1.36) 0.518  
Model 3 1 0.95 (0.62-1.45) 0.84 (0.54-1.30) 0.77 (0.50-1.20) 0.208  
Stroke deaths, n 102 102 103 110 
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Model 1 1 0.93 (0.71-1.23) 1.00 (0.76-1.31) 0.93 (0.71-1.22) 0.734  
Model 2 1 0.91 (0.69-1.20) 0.97 (0.74-1.28) 0.87 (0.66-1.14) 0.394  
Model 3 1 0.90 (0.68-1.18) 0.95 (0.72-1.26) 0.81 (0.61-1.07) 0.184  
Model 1 was adjusted for age and sex. Model 2 was adjusted for variables in Model 1 plus smoking status, drinking status, systolic blood pressure, blood 
glucose, serum total cholesterol, body mass index, antihypertensive medication status and residential area. Model 3 was adjusted for variables in Model 2 plus 
dietary intakes of saturated fatty acids (%kcal), total n-6 PUFA (%kcal), vegetable protein (%kcal), total dietary fiber (g/1,000kcal) and sodium 
(mg/1,000kcal). 
EPA, eicosapentaenoic acid; HR, hazard ratio; CI, confidence interval; PUFA, polyunsaturated fatty acid.
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Online Supplement Table 4. Multivariate-adjusted HRs and 95% CIs of mortality from total cardiovascular diseases, coronary heart disease and 
stroke according to quartiles of docosahexaenoic acid: NIPPON DATA80 
  Quartiles of DHA intake P value for trend 
  Q1 (Low) Q2 Q3 Q4 (High) 
Range of DHA intake, %kcal 
Men 0.00-0.15 0.16-0.22 0.23-0.31 0.32-1.39 
Women 0.01-0.16 0.17-0.23 0.24-0.34 0.35-1.45 
Person-years 49413  46366  50022  47097  
Total cardiovascular disease deaths, n 234 198 221 226 
  Model 1 1 0.91 (0.75-1.10) 0.88 (0.73-1.06) 0.90 (0.75-1.07) 0.267  
  Model 2 1 0.88 (0.73-1.07) 0.86 (0.72-1.04) 0.85 (0.70-1.02) 0.099  
  Model 3 1 0.87 (0.72-1.05) 0.84 (0.69-1.01) 0.79 (0.65-0.96) 0.023  
Coronary heart disease deaths, n 40 43 44 44 
  Model 1 1 1.15 (0.74-1.76) 1.01 (0.66-1.55) 1.01 (0.66-1.55) 0.842 
  Model 2 1 1.11 (0.72-1.71) 0.96 (0.63-1.48) 0.94 (0.61-1.44) 0.565 
  Model 3 1 1.06 (0.68-1.63) 0.90 (0.58-1.39) 0.82 (0.53-1.29) 0.261 
Stroke deaths, n 109 89 113 106 
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  Model 1 1 0.88 (0.66-1.16) 0.97 (0.75-1.27) 0.91 (0.69-1.18) 0.626  
  Model 2 1 0.83 (0.63-1.11) 0.94 (0.72-1.23) 0.83 (0.63-1.09) 0.292  
  Model 3 1 0.82 (0.62-1.09) 0.91 (0.70-1.19) 0.77 (0.58-1.02) 0.121  
Model 1 was adjusted for age and sex. Model 2 was adjusted for variables in Model 1 plus smoking status, drinking status, systolic blood pressure, blood 
glucose, serum total cholesterol, body mass index, antihypertensive medication status and residential area. Model 3 was adjusted for variables in Model 2 plus 
dietary intake of saturated fatty acids (%kcal), total n-6 PUFA (%kcal), vegetable protein (%kcal), total dietary fiber (g/1,000kcal) and sodium (mg/1,000kcal). 
DHA, docosahexaenoic acid; HR, hazard ratio; CI, confidence interval; PUFA, polyunsaturated fatty acid. 
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